Citations (25)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (6)
Paraskevi Panagopoulou & Emmanuel Roilides. (2022) Evaluating posaconazole, its pharmacology, efficacy and safety for the prophylaxis and treatment of fungal infections. Expert Opinion on Pharmacotherapy 23:2, pages 175-199.
Read now
Read now
Ruth Van Daele, Isabel Spriet & Johan Maertens. (2020) Posaconazole in prophylaxis and treatment of invasive fungal infections: a pharmacokinetic, pharmacodynamic and clinical evaluation. Expert Opinion on Drug Metabolism & Toxicology 16:7, pages 539-550.
Read now
Read now
Suganthini Krishnan Natesan & Pranatharthi H Chandrasekar. (2016) Isavuconazole for the treatment of invasive aspergillosis and mucormycosis: current evidence, safety, efficacy, and clinical recommendations. Infection and Drug Resistance 9, pages 291-300.
Read now
Read now
Diego R Falci & Alessandro C Pasqualotto. (2013) Profile of isavuconazole and its potential in the treatment of severe invasive fungal infections. Infection and Drug Resistance 6, pages 163-174.
Read now
Read now
Pauline L Jacinto & Pranatharthi Chandrasekar. (2013) Safety of posaconazole
. Expert Opinion on Drug Safety 12:2, pages 265-274.
Read now
Read now
Emily Zoller, Connie Valente, Kyle Baker & Michael E Klepser. (2010) Development, clinical utility, and place in therapy of posaconazole for prevention and treatment of invasive fungal infections. Drug Design, Development and Therapy 4, pages 299-311.
Read now
Read now
Articles from other publishers (19)
Diego Peña-Lorenzo, Noemí Rebollo, José Germán Sánchez-Hernández, Aránzazu Zarzuelo-Castañeda, Lourdes Vázquez-López, María José Otero & Jonás Samuel Pérez-Blanco. (2021) Population Pharmacokinetics of a Posaconazole Tablet Formulation in Transplant Adult Allogeneic Stem Cell Recipients. European Journal of Pharmaceutical Sciences, pages 106049.
Crossref
Crossref
Mateja Kraljevic, Nina Khanna, Michael Medinger, Jakob Passweg, Stavroula Masouridi-Levrat, Yves Chalandon, Nicolas J Mueller, Urs Schanz, Nathalie Vernaz, Christian Van Delden, Dionysios Neofytos, Amico Patrizia, Axel Andres, Aubert John-David, Banz Vanessa, Sonja Beckmann, Beldi Guido, Benden Christian, Berger Christoph, Binet Isabelle, Bochud Pierre-Yves, Branca Sanda, Bucher Heiner, Carrel Thierry, Catana Emmanuelle, Chalandon Yves, Geest Sabina de, Rougemont Olivier de, Dickenmann Michael, Lynn Dreifuss Joëlle, Duchosal Michel, Fehr Thomas, Ferrari-Lacraz Sylvie, Leichtle Alexander, Garzoni Christian, Gasche Soccal Paola, Gaudet Christophe, Giostra Emiliano, Golshayan Déla, Hadaya Karine, Halter Jörg, Hauri Dimitri, Heim Dominik, Hess Christoph, Hillinger Sven, Hirsch Hans, Hirt Patricia, Hofbauer Günther, Huynh-Do Uyen, Immer Franz, Koller Michael, Laesser Bettina, Lang Brian, Lehmann Roger, Lovis Christian, Manuel Oriol, Marti Hans-Peter, Martin Pierre Yves, Martinelli Michele, Mellac Katell, Meylan Pascal, Merçay Aurélia, Mettler Karin, Mueller Nicolas, M Antoniaüller, M Thomasüller, Müller-Arndt Ulrike, Müllhaupt Beat, Nägeli Mirjam, Pascual Manuel, Posfay-Barbe Klara, Rick Juliane, Rosselet Anne, Rossi Simona, Rothlin Silvia, Ruschitzka Frank, Schanz Urs, Schaub Stefan, Schnyder Aurelia, Simonetta Federico, Staufer Katharina, Steiger Jürg, Stirniman Guido, Toso Christian, Delden Christian Van, Venetz Jean-Pierre, Villard Jean, Wick Madeleine, Wilhlem Markus & Yerly Patrick. (2021) Clinical considerations on posaconazole administration and therapeutic drug monitoring in allogeneic hematopoietic cell transplant recipients. Medical Mycology 59:7, pages 701-711.
Crossref
Crossref
Sumit Bhatnagar, Dwaipayan Mukherjee, Ahmed Hamed Salem, Dale Miles, Rajeev M. Menon & John P. Gibbs. (2021) Dose adjustment of venetoclax when co-administered with posaconazole: clinical drug–drug interaction predictions using a PBPK approach. Cancer Chemotherapy and Pharmacology 87:4, pages 465-474.
Crossref
Crossref
Lu Chen, Elke H. J. Krekels, Paul. E. Verweij, Jochem B. Buil, Catherijne A. J. Knibbe & Roger J. M. Brüggemann. (2020) Pharmacokinetics and Pharmacodynamics of Posaconazole. Drugs 80:7, pages 671-695.
Crossref
Crossref
Zorica Jović, Slobodan M. Janković, Dejana Ružić Zečević, Dragan Milovanović, Srđan Stefanović, Marko Folić, Jasmina Milovanović & Marina Kostić. (2018) Clinical Pharmacokinetics of Second-Generation Triazoles for the Treatment of Invasive Aspergillosis and Candidiasis. European Journal of Drug Metabolism and Pharmacokinetics 44:2, pages 139-157.
Crossref
Crossref
Nikolaos Spernovasilis & Diamantis Kofteridis. (2018) Pre-Existing Liver Disease and Toxicity of Antifungals. Journal of Fungi 4:4, pages 133.
Crossref
Crossref
Fekade B. Sime, Janine Stuart, Jenie Butler, Therese Starr, Steven C. Wallis, Saurabh Pandey, Jeffrey Lipman & Jason A. Roberts. (2018) Pharmacokinetics of Intravenous Posaconazole in Critically Ill Patients. Antimicrobial Agents and Chemotherapy 62:6.
Crossref
Crossref
Roger J. M. Brüggemann, Dylan W. de Lange & Jan-Willem C. Alffenaar. 2018. Antibiotic Pharmacokinetic/Pharmacodynamic Considerations in the Critically Ill. Antibiotic Pharmacokinetic/Pharmacodynamic Considerations in the Critically Ill
213
238
.
Pitchaya Dilokpattanamongkol, Panadda Panusitthikorn, Rasda Boonprasert, Methee Chayakulkeeree & Porpon Rotjanapan. (2017) A case report of intravenous posaconazole in hepatic and renal impairment patient with invasive Aspergillus terreus infection: safety and role of therapeutic drug monitoring. BMC Pharmacology and Toxicology 18:1.
Crossref
Crossref
José Ramón Azanza, Belén Sádaba & Almudena Gómez-Guíu. (2014) Farmacología de los antifúngicos en el tratamiento de la aspergilosis. Revista Iberoamericana de Micología 31:4, pages 255-261.
Crossref
Crossref
Xuejun Chen, Jack G. Shi, Thomas Emm, Peggy A. Scherle, Ryan F. McGee, Yvonne Lo, Robert R. Landman, Naresh G. Punwani, William V. Williams & Swamy Yeleswaram. (2014) Pharmacokinetics and pharmacodynamics of orally administered ruxolitinib (INCB018424 phosphate) in renal and hepatic impairment patients. Clinical Pharmacology in Drug Development 3:1, pages 34-42.
Crossref
Crossref
Shang-Yi Lin, Po-Liang Lu, Kun-Bow Tsai, Chun-Yu Lin, Wei-Ru Lin, Tun-Chieh Chen, Ya-Ting Chang, Chung-Hao Huang, Chi-Yu Chen, Chung-Chih Lai & Yen-Hsu Chen. (2012) A Mucormycosis Case in a Cirrhotic Patient Successfully Treated with Posaconazole and Review of Published Literature. Mycopathologia 174:5-6, pages 499-504.
Crossref
Crossref
Michael E. Klepser. (2012) Pharmacological and Host Considerations in the Selection of Dose and Duration of Azole Therapy for Adult Patients. Current Fungal Infection Reports 6:2, pages 127-132.
Crossref
Crossref
Aspasia Katragkou, Fotini Tsikopoulou, Emmanuel Roilides & Theoklis E. Zaoutis. (2011) Posaconazole: when and how? The clinician’s view. Mycoses 55:2, pages 110-122.
Crossref
Crossref
Kerstin Yvonne Beste, Olaf Burkhardt & Volkhard Kaever. (2012) Rapid HPLC–MS/MS method for simultaneous quantitation of four routinely administered triazole antifungals in human plasma. Clinica Chimica Acta 413:1-2, pages 240-245.
Crossref
Crossref
Sandrine Lefeuvre, Mohammed-Larbi Jelassi, Amine Benlmouden, Maud Berge, Chantal Le Guellec & Eliane M. Billaud. (2011) Niveau de preuve du suivi thérapeutique pharmacologique du posaconazole. Therapies 66:2, pages 115-122.
Crossref
Crossref
Hans-Peter LippDrDr. (2011) Posaconazole: clinical pharmacokinetics and drug interactions. Mycoses 54, pages 32-38.
Crossref
Crossref
Hans-Peter Lipp. (2010) Clinical pharmacodynamics and pharmacokinetics of the antifungal extended-spectrum triazole posaconazole: an overview. British Journal of Clinical Pharmacology 70:4, pages 471-480.
Crossref
Crossref
Jason M. Cota & David S. Burgess. (2010) Antifungal Dose Adjustment in Renal and Hepatic Dysfunction: Pharmacokinetic and Pharmacodynamic Considerations. Current Fungal Infection Reports 4:2, pages 120-128.
Crossref
Crossref